TY - JOUR
T1 - A comparison of the properties of a Bcl-xL variant to the wild-type anti-apoptosis inhibitor in mammalian cell cultures
AU - Figueroa, Bruno
AU - Sauerwald, T. M.
AU - Oyler, G. A.
AU - Hardwick, J. Marie
AU - Betenbaugh, Michael J.
N1 - Funding Information:
The authors thank Dr. Craig Thompson for providing pSFFV-bcl-xLΔ and 2A1 anti-bcl-x L antibody. BF was supported by a doctoral program fellowship of the Southern Regional Educational Board. This study was sponsored by National Science Foundation (Grant no. BES-0001967).
PY - 2003/10
Y1 - 2003/10
N2 - The overexpression of bcl-2 and its homologues is a widely used strategy to inhibit apoptosis in mammalian cell culture systems. In this study, we have evaluated the Bcl-2 homologue, Bcl-xL and compared its effectiveness to a BCl-XL mutant lacking most of the non-conserved unstructured loop domain, Bcl-XLΔ (deletion of amino acids 26 through 83). The cell line, Chinese hamster ovary (CHO), was genetically modified to express constitutively BCl-XL or the BCl-XL variant and subjected to model apoptotic insults including Sindbis virus (SV) infection, gradual serum withdrawal, and serum deprivation. When cells were engineered to overexpress Bcl-xLΔ, cell death due to the SV was inhibited, and Bcl-xLΔ provided comparable protection to the wild-type BCl-XL even though expression levels were much lower for the mutant. Furthermore, the cells expressing Bcl-xLΔ continued to proliferate following infection while CHO-bcl-xL ceased proliferation immediately following infection. As a result, total production of a heterologous protein encoded on the SV was highest in cell lines expressing Bcl-xLΔ. Cells expressing the variant Bcl-xL also continued to proliferate and showed increased viable cell numbers following gradual serum withdrawal. In contrast, wild-type BCl-XL expressing CHO cells were found to arrest growth but maintain viability following serum withdrawal. Interestingly, CHO cells expressing Bcl-XLΔ were also able to recover and return to rapid growth rates much faster than either the wild-type CHO-bcl-xL or CHO following the replenishment of fresh complete medium containing 10% FBS. Confocal imaging of yellow fluorescent protein (YFP) fused to the N terminus of BCl-XL and Bcl-X LΔ indicated dense aggregates of the Bcl-XLΔ while the wild-type protein was distributed throughout the cell in a manner resembling transmembrane localization. As an alternative to complete removal of the loop domain, BCl-XL variants were created in which aspartate residues containing potential caspase recognition sites within the loop domain of Bcl-xL were removed. Cell populations expressing various Bcl-XL-Asp mutants were exposed to an apoptotic spent medium stimulus, and the cells expressing these Bcl-xL variants provided increased viabilities as compared to cells containing wild-type BCl-X L protein. These studies indicate that modification of anti-apoptotic genes can affect multiple cellular properties including response to apoptotic stimuli and cell growth. This knowledge can be valuable in the design of improved apoptosis inhibitors for biotechnology applications.
AB - The overexpression of bcl-2 and its homologues is a widely used strategy to inhibit apoptosis in mammalian cell culture systems. In this study, we have evaluated the Bcl-2 homologue, Bcl-xL and compared its effectiveness to a BCl-XL mutant lacking most of the non-conserved unstructured loop domain, Bcl-XLΔ (deletion of amino acids 26 through 83). The cell line, Chinese hamster ovary (CHO), was genetically modified to express constitutively BCl-XL or the BCl-XL variant and subjected to model apoptotic insults including Sindbis virus (SV) infection, gradual serum withdrawal, and serum deprivation. When cells were engineered to overexpress Bcl-xLΔ, cell death due to the SV was inhibited, and Bcl-xLΔ provided comparable protection to the wild-type BCl-XL even though expression levels were much lower for the mutant. Furthermore, the cells expressing Bcl-xLΔ continued to proliferate following infection while CHO-bcl-xL ceased proliferation immediately following infection. As a result, total production of a heterologous protein encoded on the SV was highest in cell lines expressing Bcl-xLΔ. Cells expressing the variant Bcl-xL also continued to proliferate and showed increased viable cell numbers following gradual serum withdrawal. In contrast, wild-type BCl-XL expressing CHO cells were found to arrest growth but maintain viability following serum withdrawal. Interestingly, CHO cells expressing Bcl-XLΔ were also able to recover and return to rapid growth rates much faster than either the wild-type CHO-bcl-xL or CHO following the replenishment of fresh complete medium containing 10% FBS. Confocal imaging of yellow fluorescent protein (YFP) fused to the N terminus of BCl-XL and Bcl-X LΔ indicated dense aggregates of the Bcl-XLΔ while the wild-type protein was distributed throughout the cell in a manner resembling transmembrane localization. As an alternative to complete removal of the loop domain, BCl-XL variants were created in which aspartate residues containing potential caspase recognition sites within the loop domain of Bcl-xL were removed. Cell populations expressing various Bcl-XL-Asp mutants were exposed to an apoptotic spent medium stimulus, and the cells expressing these Bcl-xL variants provided increased viabilities as compared to cells containing wild-type BCl-X L protein. These studies indicate that modification of anti-apoptotic genes can affect multiple cellular properties including response to apoptotic stimuli and cell growth. This knowledge can be valuable in the design of improved apoptosis inhibitors for biotechnology applications.
KW - Apoptosis
KW - Bcl-2 family
KW - Bcl-x
KW - CHO
KW - Caspases
KW - Chinese Hamster Ovary cells
KW - Mammalian cell culture
KW - Serum deprivation
KW - Sindbis virus infection
KW - Spent medium
UR - http://www.scopus.com/inward/record.url?scp=1442344781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1442344781&partnerID=8YFLogxK
U2 - 10.1016/S1096-7176(03)00044-2
DO - 10.1016/S1096-7176(03)00044-2
M3 - Article
C2 - 14642351
AN - SCOPUS:1442344781
SN - 1096-7176
VL - 5
SP - 230
EP - 245
JO - Metabolic Engineering
JF - Metabolic Engineering
IS - 4
ER -